Partnership Opportunities

Partnership with Ocular Therapeutix

Ocular Therapeutix, Inc. is a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye. Using our proprietary bioresorbable hydrogel-based formulation technology ELUTYXTM, we are advancing the field of ophthalmology by addressing critical unmet needs in eye care. 

Areas of Interest

We are interested in licensing or acquiring ophthalmology assets consistent with our corporate strategy to
broaden our portfolio. Our areas of interest include:

Geographic atrophy

Age-related macular degeneration

Rare retinal diseases

Hydrogel background
handshake agreement

Leaders in Development

As a leader in the development of innovative treatments for ophthalmic diseases, we welcome discussions with key partners to enable the expansion of patient care options in the field. We are open to scientific, research, and commercial partnerships of our products and drug delivery technologies.

Current Partnerships

We are open to partnerships for our product candidates outside of the United States. We currently have a partnership with AffaMed for the development and commercialization of two of our product candidates, DEXTENZA® (dexamethasone ophthalmic insert) and OTX-TIC* (travoprost intracameral implant), in Greater China, South Korea, and the ASEAN markets.

*PAXTRAVA™ (travoprost intracameral implant), also referenced as laboratory code OTX-TIC

AffaMed logo

Find out more about partnerships